Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
McKesson
Harvard Business School
AstraZeneca
Boehringer Ingelheim

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,923,218

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,923,218
Title:Modulation of the integrin linked kinase signaling pathway to promote cardiac cell proliferation and self-renewal
Abstract: Modulation of the integrin-linked kinase (ILK) signaling pathway is used to enhance the remodeling process relevant to a wide range of cardiac diseases. More specifically, a process to instigate beneficial human cardiac hypertrophy or for post myocardial infarction (MI) remodeling comprising illiciting an overexpression of ILK, is described. The ILK signaling pathway is also used as a means for cardiac stem cell proliferation and self-renewal.
Inventor(s): Coles; John G. (Toronto, CA), Hannigan; Gregory (Toronto, CA), Lu; Huanzhang (Toronto, CA)
Assignee: Coles; John G. (Toronto, Ontario, CA)
Application Number:11/915,687
Patent Claims:1. A method for inducing beneficial human cardiac hypertrophy in an individual by way of the integrin linked kinase (ILK) pathway comprising the following steps: (a) culturing in vitro one or more dissociated heart tissue cells derived from a first individual; (b) infecting the one or more dissociated heart tissue cells with an adenovirus vector encoding an integrin linked kinase (ILK) gene; and (c) administering the one or more infected heart tissue cells to a second individual.

2. The method of claim 1 which further includes eliciting an overexpression of ILK in the one or more infected heart tissue cells.

3. The method of claim 1, wherein the culturing step (a) comprises culturing the dissociated heart tissue cells in serum-free medium supplemented with fetal bovine serum.

4. The method of claim 1, further comprising the step of (d) dissociating a heart tissue sample derived from the individual to form the one or more dissociated heart tissue cells comprising enzymatic digestion with trypsin and/or Type II collagenase, wherein step (d) is performed prior to step (a).

5. The method of claim 4, wherein the heart tissue derived from the individual is further minced and washed before enzymatic digestion during step (d).

6. The method of claim 4, further comprising the step of (e) removing fibroblasts from the one or more dissociated heart tissue cells, wherein step (e) is performed prior to step (a) but after step (d).

7. The method of claim 6, wherein step (e) is performed by culturing the one or more dissociated heart tissue cells in a pre-coated plate or dish and removing the supernatant of the culture from the pre-coated plate or dish for culturing in step (a).

8. The method of claim 1, wherein the infecting step (b) is performed after the culture in step (a) reaches a confluency of between about 50% and about 70%.

9. The method of claim 1, wherein the infecting step (b) is performed after culturing the one or more dissociated heart tissue cells for about 2 to 4 days in step (a).

10. The method of claim 1, wherein the infecting step (b) is performed with a multiplicity of infection of between about 1.5 and 2.0.

11. The method of claim 1, wherein the one or more heart tissue cells are infected in a serum-free medium supplemented with fetal bovine serum during step (b).

12. The method of claim 1, wherein the one or more heart tissue cells are infected with 10 pfu/ml of adenovirus vector during step (b).

13. The method of claim 1, wherein the adenovirus comprises a replication-deficient serotype 5 adenovirus.

14. The method of claim 1, wherein the integrin linked kinase (ILK) gene is a human ILK gene.

15. The method of claim 1, wherein the integrin linked kinase (ILK) gene is a wild-type human ILK gene.

16. The method of claim 1, wherein the one or more heart tissue cells infected with the adenovirus vector encoding the integrin linked kinase (ILK) gene in step (b) have a greater number of c-Kit-positive cells compared to heart tissue cells infected with an empty adenovirus vector that does not encode an integrin linked kinase (ILK) gene.

17. The method of claim 1, wherein the one or more heart tissue cells infected with the adenovirus vector encoding the integrin linked kinase (ILK) gene in step (b) have an increase in GTP-bound Rac-1 compared to heart tissue cells infected with an empty adenovirus vector that does not encode an integrin linked kinase (ILK) gene.

18. The method of claim 17, wherein the increase in GTP-bound Rac-1 in the one or more heart tissue cells infected with the adenovirus vector encoding the integrin linked kinase (ILK) gene in step (b) is blocked by treatment with KP-392.

19. The method of claim 1, wherein the one or more heart tissue cells infected with the adenovirus vector encoding the integrin linked kinase (ILK) gene in step (b) have an increase in GTP-bound Cdc42 compared to heart tissue cells infected with an empty adenovirus vector that does not encode an integrin linked kinase (ILK) gene.

20. The method of claim 19, wherein the increase in GTP-bound Cdc42 in the one or more heart tissue cells infected with the adenovirus vector encoding the integrin linked kinase (ILK) gene in step (b) is blocked by treatment with KP-392.

21. The method of claim 1, wherein the one or more heart tissue cells infected with the adenovirus vector encoding the integrin linked kinase (ILK) gene in step (b) form a greater number of anchorage-independent primary cardiospheres when cultured in a medium containing fibroblast growth factor (FGF) and epidermal growth factor (EGF) in comparison to heart tissue cells infected with an empty adenovirus vector that does not encode an integrin linked kinase (ILK) gene.

22. The method of claim 1, wherein the subject first individual and the second individual are human.

23. The method of claim 22, wherein the first individual and the second individual are the same person.

24. The method of claim 1, wherein the one or more infected heart tissue cells are administered to the heart of the second individual in step (c).

25. A method for inducing beneficial human cardiac hypertrophy in an individual by way of the integrin linked kinase (ILK) pathway comprising the following steps: (a) culturing in vitro one or more dissociated heart tissue cells derived from a first individual; (b) infecting the one or more dissociated heart tissue cells with an adenovirus vector encoding an integrin linked kinase (ILK) gene; and (c) transplanting the one or more infected heart tissue cells to the heart of a second individual.

26. The method of claim 25, wherein the first individual and the second individual are the same individual.

27. The method of claim 25, wherein the first individual and the second individual are human.

28. A method for inducing beneficial human cardiac hypertrophy in an individual by way of the integrin linked kinase (ILK) pathway comprising the following steps: (a) infecting one or more dissociated heart tissue cells cultured in vitro from a first individual with an adenovirus vector encoding an integrin linked kinase (ILK) gene; and (b) administering the one or more infected heart tissue cells to a second individual.

29. The method of claim 28, wherein the first individual and the second individual are the same individual.

30. The method of claim 28, wherein the first individual and the second individual are human.

31. A method for inducing beneficial human cardiac hypertrophy in an individual by way of the integrin linked kinase (ILK) pathway comprising the following steps: (a) culturing in vitro one or more dissociated heart tissue cells derived from the individual; (b) infecting the one or more dissociated heart tissue cells with an adenovirus vector encoding an integrin linked kinase (ILK) gene; and (c) administering the one or more infected heart tissue cells to the individual.

32. The method of claim 31, wherein the individual is a human.

33. A method for inducing beneficial human cardiac hypertrophy in a second individual by way of the integrin linked kinase (ILK) pathway comprising the following steps: (a) culturing in vitro one or more dissociated heart tissue cells derived from a first individual; (b) infecting the one or more dissociated heart tissue cells with an adenovirus vector encoding an integrin linked kinase (ILK) gene; and (c) administering the one or more infected heart tissue cells to the second individual.

34. The method claim 33, wherein the first individual and the second individual are the same individual.

35. The method of claim 33, wherein the first individual and the second individual are human.

Summary for Patent:   Start Trial

PCT Information
PCT FiledMay 29, 2006PCT Application Number:PCT/CA2006/000868
PCT Publication Date:November 30, 2006PCT Publication Number:WO2006/125321

Details for Patent 7,923,218

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Advance Biofactures SANTYL collagenase VIAL 101995 001 1965-06-04   Start Trial Coles; John G. (Toronto, Ontario, CA) 2036-04-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,923,218

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Moodys
AstraZeneca
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.